Get the Stockscreener App
2.85
5.17%
0.14
After Hours:
2.80
-0.05
-1.75%
Abcellera Biologics Inc stock is traded at $2.85, with a volume of 2.07M.
It is up +5.17% in the last 24 hours and up +6.74% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$2.71
Open:
$2.7
24h Volume:
2.07M
Relative Volume:
0.92
Market Cap:
$841.79M
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-6.3333
EPS:
-0.45
Net Cash Flow:
$-121.38M
1W Performance:
+1.42%
1M Performance:
+6.74%
6M Performance:
-3.06%
1Y Performance:
-47.51%
1-Day Range:
$2.6818
$2.88
1-Week Range:
$2.62
$3.00
52-Week Range:
$2.335
$6.055
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
2215 YUKON STREET, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.85 | 841.79M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 3.3%Still a Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap UpHere's What Happened - MarketBeat
Walleye Capital LLC Makes New $668,000 Investment in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics (FRA:8QQ) Price-to-Owner-Earnings : (As of Dec. 07, 2024) - GuruFocus.com
PDT Partners LLC Sells 173,884 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year By Investing.com - Investing.com Canada
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year - Investing.com India
AbCellera Biologics (FRA:8QQ) Degree of Operating Leverage : -1.44 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Debt : $3.95 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Pre-Tax Income : $-202.17 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Capex-to-Revenue : 2.85 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Buildings And Improvements : $66.92 Mil (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Revenue per Share : $0.11 (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Change In Receivables : $-64.70 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Debt-to-Equity : 0.07 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Owner Earnings per Share (TTM) : -0.61 (As of Sep. 2024) - GuruFocus.com
AbCellera to Present at Upcoming Investor Conferences in December and January - Devon Dispatch
AbCellera to Present at Major Healthcare Conferences: Piper Sandler and JPM 2024-25 - StockTitan
ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Bloom Burton Cuts Earnings Estimates for AbCellera Biologics - MarketBeat
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 - Business Wire
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings - MarketBeat
AbCellera Unveils Breakthrough T-Cell Platform Data, Shows Promise in Cancer Treatment - StockTitan
AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at Benchmark - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Given "Buy" Rating at Stifel Nicolaus - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
AbCellera stock price target cut, keeps Outperform on strategic pivot By Investing.com - Investing.com UK
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Earnings call: AbCellera reports steady Q3 2024 revenue amidst R&D growth - Investing.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Developments - GuruFocus.com
AbCellera Reports Q3 2024 Business Results - The Globe and Mail
AbCellera Biologics Reports Q3 2024 Financial Results - TipRanks
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript - Nasdaq
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Abcellera Biologics earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):